A Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
Brief Description Of Study
We are doing this study to find out if lenabasum can help people with diffuse cutaneous systemic sclerosis (SSc) by stopping chronic inflammation. We also want to find out if lenabasum is safe to take without causing too many side effects. Patients will be in this study for 1 year and have 13 study visits. Lenabasum is an experimental, or investigational, drug. This means that lenabasum is not approved by the U.S. Food and Drug Administration (FDA) and can only be used in research studies. This research study will compare lenabasum to placebo. The placebo looks exactly like lenabasum, but does not contain lenabasum.